Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 2.4.2.28 - S-methyl-5'-thioadenosine phosphorylase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Adenocarcinoma of Lung
MTAP-deficiency could predict better treatment response in advanced lung adenocarcinoma patients initially treated with pemetrexed-platinum chemotherapy and bevacizumab.
Adenoma
[Expression of methylthioadenosine phosphorylase (MTAP) gene and demethylation of its promoter in human colorectal cancer.]
Adenomatous Polyposis Coli
Transition state analogue of MTAP extends lifespan of APCMin/+ mice.
Astrocytoma
Expression of Methylthioadenosine Phosphorylase (MTAP) in Pilocytic Astrocytomas.
Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma.
Biliary Tract Neoplasms
Homozygous deletions of methylthioadenosine phosphorylase in human biliary tract cancers.
Breast Neoplasms
Methylthioadenosine phosphorylase in human breast cancer.
Methylthioadenosine phosphorylase, a gene frequently codeleted with p16(cdkN2a/ARF), acts as a tumor suppressor in a breast cancer cell line.
Carcinoma
5'-deoxy-5'-methylthioadenosine phosphorylase--II. Role of the enzyme in the metabolism and antineoplastic action of adenine-substituted analogs of 5'-deoxy-5'-methylthioadenosine.
Codeletion of the genes for p16INK4, methylthioadenosine phosphorylase, interferon-alpha1, interferon-beta1, and other 9p21 markers in human malignant cell lines.
Expression and localisation of methylthioadenosine phosphorylase (MTAP) in oral squamous cell carcinoma and their significance in epithelial-to-mesenchymal transition.
Gene deletion chemoselectivity: codeletion of the genes for p16(INK4), methylthioadenosine phosphorylase, and the alpha- and beta-interferons in human pancreatic cell carcinoma lines and its implications for chemotherapy.
Immunohistochemical diagnosis of methylthioadenosine phosphorylase (MTAP) deficiency in non-small cell lung carcinoma.
Loss of Methylthioadenosine Phosphorylase by Immunohistochemistry Is Common in Pulmonary Sarcomatoid Carcinoma and Sarcomatoid Mesothelioma.
Methylthioadenosine phosphorylase expression in cutaneous squamous cell carcinoma.
Methylthioadenosine phosphorylase inactivation depends on gene deletion in laryngeal squamous cell carcinoma.
Strong expression of methylthioadenosine phosphorylase (MTAP) in human colon carcinoma cells is regulated by TCF1/[beta]-catenin.
Carcinoma, Hepatocellular
Down-regulation of methylthioadenosine phosphorylase (MTAP) induces progression of hepatocellular carcinoma via accumulation of 5'-deoxy-5'-methylthioadenosine (MTA).
Promoter-hypermethylation is causing functional relevant downregulation of methylthioadenosine phosphorylase (MTAP) expression in hepatocellular carcinoma.
Carcinoma, Non-Small-Cell Lung
Homozygous deletions of methylthioadenosine phosphorylase (MTAP) are more frequent than p16INK4A (CDKN2) homozygous deletions in primary non-small cell lung cancers (NSCLC).
Immunohistochemical diagnosis of methylthioadenosine phosphorylase (MTAP) deficiency in non-small cell lung carcinoma.
[Expression and clinical significance of methylthioadenosine phosphorylase gene in patients with non-small cell lung cancer]
Carcinoma, Squamous Cell
Methylthioadenosine phosphorylase expression in cutaneous squamous cell carcinoma.
Chondrosarcoma
Methylthioadenosine phosphorylase gene deletions are frequently detected by fluorescence in situ hybridization in conventional chondrosarcomas.
Chordoma
Methylthioadenosine phosphorylase and activated insulin-like growth factor-1 receptor/insulin receptor: potential therapeutic targets in chordoma.
Colorectal Neoplasms
[Expression of methylthioadenosine phosphorylase (MTAP) gene and demethylation of its promoter in human colorectal cancer.]
Coronary Artery Disease
Association between rs10118757(A/G) in methylthioadenosine phosphorylase gene and coronary artery disease in Chinese Hans.
Fanconi Anemia
Epigenetic regulation of Fanconi anemia genes implicates PRMT5 blockage as a strategy for tumor chemosensitization.
Fibrosarcoma
Quantitation of cellular metabolic fluxes of methionine.
Glioblastoma
A PRMT5-RNF168-SMURF2 Axis Controls H2AX Proteostasis.
Epigenetic regulation of Fanconi anemia genes implicates PRMT5 blockage as a strategy for tumor chemosensitization.
Homozygous MTAP deletion in primary human glioblastoma is not associated with elevation of methylthioadenosine.
MTAP Loss Promotes Stemness in Glioblastoma and Confers Unique Susceptibility to Purine Starvation.
Glioma
Absence of methylthioadenosine phosphorylase in human gliomas.
Codeletion of the genes for p16INK4, methylthioadenosine phosphorylase, interferon-alpha1, interferon-beta1, and other 9p21 markers in human malignant cell lines.
Homozygous loss of the interferon genes defines the critical region on 9p that is deleted in lung cancers.
Loss of 5'-Methylthioadenosine Phosphorylase (MTAP) is Frequent in High-Grade Gliomas; Nevertheless, it is Not Associated with Higher Tumor Aggressiveness.
Midline Glioma in Adults: Clinicopathological, Genetic, and Epigenetic Analysis.
Molecular genetic analysis of chromosome 9p in methylthioadenosine phosphorylase deficient glioma cell lines.
Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma.
Head and Neck Neoplasms
A transition state analogue of 5'-methylthioadenosine phosphorylase induces apoptosis in head and neck cancers.
Hematologic Neoplasms
Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity: Current strategies.
Ischemic Stroke
MTAP gene is associated with ischemic stroke in Chinese Hans.
Keratosis
Losses of 3p14 and 9p21 as shown by fluorescence in situ hybridization are early events in tumorigenesis of oral squamous cell carcinoma and already occur in simple keratosis.
Leukemia
5'-deoxy-5'-methylthioadenosine phosphorylase deficiency in leukemia: genetics and biochemical aspects.
5'-Deoxy-5'-methylthioadenosine phosphorylase--III. Role of the enzyme in the metabolism and action of 5'-halogenated adenosine analogs.
5'-deoxy-5'-methylthioadenosine phosphorylase--V. Acycloadenosine derivatives as inhibitors of the enzyme.
A polymorphic region defined by pCN2 (the 3' nontranslated region of N-ras) maps to chromosome 9cen-p12.
Absence of methylthioadenosine phosphorylase in human gliomas.
Chemotherapy targeting methylthioadenosine phosphorylase (MTAP) deficiency in adult T cell leukemia (ATL).
Codeletion of the genes for p16INK4, methylthioadenosine phosphorylase, interferon-alpha1, interferon-beta1, and other 9p21 markers in human malignant cell lines.
Conversion of 5'-deoxy-5'-methylthioadenosine and 5'-deoxy-5'-methylthioinosine to methionine in cultured human leukemic cells.
Deficiency of methylthioadenosine phosphorylase in human leukemic cells in vivo.
Methylthioadenosine phosphorylase deficiency in acute leukemia: pathologic, cytogenetic, and clinical features.
Methylthioadenosine phosphorylase deficiency in human leukemias and solid tumors.
Synthesis and antiproliferative effects of novel 5'-fluorinated analogues of 5'-deoxy-5'-(methylthio)adenosine.
Targeting 5'-deoxy-5'-(methylthio)adenosine phosphorylase by 5'-haloalkyl analogues of 5'-deoxy-5'-(methylthio)adenosine.
Leukemia, Lymphoid
Comparison of the biological effects of four irreversible inhibitors of ornithine decarboxylase in two murine lymphocytic leukemia cell lines.
Methylthioadenosine phosphorylase and purine nucleoside phosphorylase in B-chronic lymphocytic leukemia.
Leukemia, T-Cell
5'-deoxy-5'-methylthioadenosine phosphorylase--II. Role of the enzyme in the metabolism and antineoplastic action of adenine-substituted analogs of 5'-deoxy-5'-methylthioadenosine.
Chemotherapy targeting methylthioadenosine phosphorylase (MTAP) deficiency in adult T cell leukemia (ATL).
Conversion of 5'-deoxy-5'-methylthioadenosine and 5'-deoxy-5'-methylthioinosine to methionine in cultured human leukemic cells.
Leukemia-Lymphoma, Adult T-Cell
The methylthioadenosine phosphorylase gene is frequently co-deleted with the p16INK4a gene in acute type adult T-cell leukemia.
Leukoplakia, Oral
Losses of 3p14 and 9p21 as shown by fluorescence in situ hybridization are early events in tumorigenesis of oral squamous cell carcinoma and already occur in simple keratosis.
Liver Cirrhosis
Methylthioadenosine phosphorylase gene expression is impaired in human liver cirrhosis and hepatocarcinoma.
Liver Diseases
Expression and function of methylthioadenosine phosphorylase in chronic liver disease.
Lung Neoplasms
Growth and metastases of human lung cancer are inhibited in mouse xenografts by a transition state analogue of 5'-methylthioadenosine phosphorylase.
Homozygous deletions of methylthioadenosine phosphorylase (MTAP) are more frequent than p16INK4A (CDKN2) homozygous deletions in primary non-small cell lung cancers (NSCLC).
Methylthioadenosine phosphorylase cDNA transfection alters sensitivity to depletion of purine and methionine in A549 lung cancer cells.
Methylthioadenosine phosphorylase deficiency in human non-small cell lung cancers.
[Expression and clinical significance of methylthioadenosine phosphorylase gene in patients with non-small cell lung cancer]
Lymphoma
A polymorphic region defined by pCN2 (the 3' nontranslated region of N-ras) maps to chromosome 9cen-p12.
Absence of methylthioadenosine phosphorylase in human gliomas.
Heterogeneity of the toxic mechanisms of methylthioadenosine in methylthioadenosine phosphorylase deficient murine lymphoma cells.
Lack of methylthioadenosine phosphorylase expression in mantle cell lymphoma is associated with shorter survival: implications for a potential targeted therapy.
Methylthioadenosine phosphorylase gene is silenced by promoter hypermethylation in human lymphoma cell line DHL-9: another mechanism of enzyme deficiency.
Modulation of adenine nucleoside excretion and incorporation in adenosine deaminase deficient human lymphoma cells.
Lymphoma, Mantle-Cell
Lack of methylthioadenosine phosphorylase expression in mantle cell lymphoma is associated with shorter survival: implications for a potential targeted therapy.
Lymphoma, T-Cell
Mice heterozygous for germ-line mutations in methylthioadenosine phosphorylase (MTAP) die prematurely of T-cell lymphoma.
Lymphoma, T-Cell, Cutaneous
Independent Loss of Methylthioadenosine Phosphorylase (MTAP) in Primary Cutaneous T-Cell Lymphoma.
Lymphoma, T-Cell, Peripheral
Lack of expression of MTAP in uncommon T-cell lymphomas.
Melanoma
Characterization of methylthioadenosin phosphorylase (MTAP) expression in malignant melanoma.
Characterization of the Methylthioadenosine Phosphorylase Polymorphism rs7023954 - Incidence and Effects on Enzymatic Function in Malignant Melanoma.
Deregulation of protein methylation in melanoma.
Distinct deletions of chromosome 9p associated with melanoma versus glioma, lung cancer, and leukemia.
Methylthioadenosine phosphorylase represents a predictive marker for response to adjuvant interferon therapy in patients with malignant melanoma.
Nucleotide-metabolism and chromosome alterations in human-malignant melanoma xenografts.
Polymorphisms in nevus-associated genes MTAP, PLA2G6, and IRF4 and the risk of invasive cutaneous melanoma.
Significantly decreased methylthioadenosine phosphorylase expression in malignant melanoma.
The metabolite 5'-methylthioadenosine signals through the adenosine receptor A2B in melanoma.
Tissue microarray analysis of methylthioadenosine phosphorylase protein expression in melanocytic skin tumors.
Mesothelioma
c-MET immunohistochemistry for differentiating malignant mesothelioma from benign mesothelial proliferations.
CD146 immunohistochemical staining for the separation of benign from malignant mesothelial proliferations.
Correlation of methylthioadenosine phosphorylase (MTAP) protein expression with MTAP and CDKN2A copy number in malignant pleural mesothelioma.
Genomic-based ancillary assays offer improved diagnostic yield of effusion cytology with potential challenges in malignant pleural mesothelioma.
Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas.
Implications of P16/CDKN2A deletion in pleural mesotheliomas.
Loss of Methylthioadenosine Phosphorylase by Immunohistochemistry Is Common in Pulmonary Sarcomatoid Carcinoma and Sarcomatoid Mesothelioma.
Malignant pleural mesothelioma with heterologous elements.
The diagnostic value of immunohistochemically detected methylthioadenosine phosphorylase deficiency in malignant pleural mesotheliomas.
The effect of a novel transition state inhibitor of methylthioadenosine phosphorylase on pemetrexed activity.
Transcriptional perturbation of protein arginine methyltransferase-5 exhibits MTAP-selective oncosuppression.
Mesothelioma, Malignant
c-MET immunohistochemistry for differentiating malignant mesothelioma from benign mesothelial proliferations.
Correlation of methylthioadenosine phosphorylase (MTAP) protein expression with MTAP and CDKN2A copy number in malignant pleural mesothelioma.
Genomic-based ancillary assays offer improved diagnostic yield of effusion cytology with potential challenges in malignant pleural mesothelioma.
Malignant mesothelioma in situ diagnosed by methylthioadenosine phosphorylase loss and homozygous deletion of CDKN2A: a case report.
The diagnostic value of immunohistochemically detected methylthioadenosine phosphorylase deficiency in malignant pleural mesotheliomas.
Transcriptional perturbation of protein arginine methyltransferase-5 exhibits MTAP-selective oncosuppression.
Usefulness of methylthioadenosine phosphorylase and BRCA-associated protein 1 immunohistochemistry in the diagnosis of malignant mesothelioma in effusion cytology specimens.
Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas.
Myocardial Infarction
Association between rs10118757(A/G) in methylthioadenosine phosphorylase gene and coronary artery disease in Chinese Hans.
MTAP and CDKN2B genes are associated with myocardial infarction in Chinese Hans.
[Association between methylthioadenosine phosphorylase gene single nucleotide polymorphisms and myocardial infarction in Chinese Han ethnicity.]
Nasopharyngeal Carcinoma
Characterization and Prognostic Significance of Methylthioadenosine Phosphorylase Deficiency in Nasopharyngeal Carcinoma.
Neoplasm Metastasis
Growth and metastases of human lung cancer are inhibited in mouse xenografts by a transition state analogue of 5'-methylthioadenosine phosphorylase.
Methylthioadenosine phosphorylase represents a predictive marker for response to adjuvant interferon therapy in patients with malignant melanoma.
Neoplasms
5'-Deoxy-5'-methylthioadenosine phosphorylase and p16INK4 deficiency in multiple tumor cell lines.
5'-deoxy-5'-methylthioadenosine phosphorylase--V. Acycloadenosine derivatives as inhibitors of the enzyme.
5-Iodoribose 1-phosphate, an analog of ribose 1-phosphate. Enzymatic synthesis and kinetic studies with enzymes of purine, pyrimidine, and sugar phosphate metabolism.
6-thioguanine: a drug with unrealized potential for cancer therapy.
A methylthioadenosine phosphorylase (MTAP) fusion transcript identifies a new gene on chromosome 9p21 that is frequently deleted in cancer.
A phase II multicenter study of L-alanosine, a potent inhibitor of adenine biosynthesis, in patients with MTAP-deficient cancer.
A potential predictive marker for response to interferon in malignant melanoma.
Absence of methylthioadenosine phosphorylase in human gliomas.
Analysis of tumor suppressor gene on human chromosome 9 in mouse x human somatic cell hybrids.
Anaplerotic reactions in tumour proliferation and apoptosis.
Characterization and Prognostic Significance of Methylthioadenosine Phosphorylase Deficiency in Nasopharyngeal Carcinoma.
Characterization of methylthioadenosin phosphorylase (MTAP) expression in malignant melanoma.
Chemical genetic screening for compounds that preferentially inhibit growth of methylthioadenosine phosphorylase (MTAP)-deficient Saccharomyces cerevisiae.
Codeletion of the genes for p16INK4, methylthioadenosine phosphorylase, interferon-alpha1, interferon-beta1, and other 9p21 markers in human malignant cell lines.
Concordant loss of MTAP and p16/CDKN2A expression in gastroesophageal carcinogenesis: evidence of homozygous deletion in esophageal noninvasive precursor lesions and therapeutic implications.
Construction of a 2.8-megabase yeast artificial chromosome contig and cloning of the human methylthioadenosine phosphorylase gene from the tumor suppressor region on 9p21.
Defects in methylthioadenosine phosphorylase are associated with but not responsible for methionine-dependent tumor cell growth.
Deficiency of 5'-deoxy-5'-methylthioadenosine phosphorylase activity in malignancy. Absence of the protein in human enzyme-deficient cell lines.
Deficiency of methylthioadenosine phosphorylase in human leukemic cells in vivo.
Delivery systems and molecular targets of mechanism-based therapies for GBM.
Deregulation of protein methylation in melanoma.
Design, Synthesis and Evaluation of AdSS Bisubstrate Inhibitors.
Detection of methylthioadenosine phosphorylase (MTAP) and p16 gene deletion in T cell acute lymphoblastic leukemia by real-time quantitative PCR assay.
Discovery of AG-270, a First-in-Class Oral MAT2A Inhibitor for the Treatment of Tumors with Homozygous MTAP Deletion.
Distinct deletions of chromosome 9p associated with melanoma versus glioma, lung cancer, and leukemia.
Down-regulation of methylthioadenosine phosphorylase (MTAP) induces progression of hepatocellular carcinoma via accumulation of 5'-deoxy-5'-methylthioadenosine (MTA).
Downregulation of methylthioadenosin phosphorylase by homozygous deletion in gastric carcinoma.
EFA (9-beta-D-erythrofuranosyladenine) is an effective salvage agent for methylthioadenosine phosphorylase-selective therapy of T-cell acute lymphoblastic leukemia with L-alanosine.
Enzyme deficiency and tumor suppressor genes: absence of 5'-deoxy-5'-methylthioadenosine phosphorylase in human tumors.
Epigenetic regulation of Fanconi anemia genes implicates PRMT5 blockage as a strategy for tumor chemosensitization.
Exploiting methionine restriction for cancer treatment.
Expression of MTAP inhibits tumor-related phenotypes in HT1080 cells via a mechanism unrelated to its enzymatic function.
Fine-mapping loss of gene architecture at the CDKN2B (p15INK4b), CDKN2A (p14ARF, p16INK4a), and MTAP genes in head and neck squamous cell carcinoma.
Frequent deletion in the methylthioadenosine phosphorylase gene in T-cell acute lymphoblastic leukemia: strategies for enzyme-targeted therapy.
Genomic cloning of methylthioadenosine phosphorylase: a purine metabolic enzyme deficient in multiple different cancers.
Germline Mutations in Mtap Cooperate with Myc to Accelerate Tumorigenesis in Mice.
Growth and metastases of human lung cancer are inhibited in mouse xenografts by a transition state analogue of 5'-methylthioadenosine phosphorylase.
Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas.
Homozygous deletions of methylthioadenosine phosphorylase (MTAP) are more frequent than p16INK4A (CDKN2) homozygous deletions in primary non-small cell lung cancers (NSCLC).
Homozygous deletions of methylthioadenosine phosphorylase in human biliary tract cancers.
Homozygous loss of the interferon genes defines the critical region on 9p that is deleted in lung cancers.
Homozygous MTAP deletion in primary human glioblastoma is not associated with elevation of methylthioadenosine.
Identification of gene expression profiles predicting tumor cell response to L-alanosine.
Implications of P16/CDKN2A deletion in pleural mesotheliomas.
Increased sensitivity to thiopurines in methylthioadenosine phosphorylase-deleted cancers.
Independent Loss of Methylthioadenosine Phosphorylase (MTAP) in Primary Cutaneous T-Cell Lymphoma.
Lack of methylthioadenosine phosphorylase expression in mantle cell lymphoma is associated with shorter survival: implications for a potential targeted therapy.
Leishmania infantum 5'-Methylthioadenosine Phosphorylase presents relevant structural divergence to constitute a potential drug target.
Loss of 5'-Methylthioadenosine Phosphorylase (MTAP) is Frequent in High-Grade Gliomas; Nevertheless, it is Not Associated with Higher Tumor Aggressiveness.
Loss of methylthioadenosine phosphorylase and elevated ornithine decarboxylase is common in pancreatic cancer.
Loss of MTAP expression is a negative prognostic marker in Ewing sarcoma family of tumors.
Losses of 3p14 and 9p21 as shown by fluorescence in situ hybridization are early events in tumorigenesis of oral squamous cell carcinoma and already occur in simple keratosis.
MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA Damage.
Methionine and Kynurenine Activate Oncogenic Kinases in Glioblastoma, and Methionine Deprivation Compromises Proliferation.
Methods to Study the Role of Methionine-Restricted Diet and Methioninase in Cancer Growth Control.
Methylthioadenosine nucleoside phosphorylase deficiency in methylthio-dependent cancer cells.
Methylthioadenosine phosphorylase cDNA transfection alters sensitivity to depletion of purine and methionine in A549 lung cancer cells.
Methylthioadenosine phosphorylase deficiency in human leukemias and solid tumors.
Methylthioadenosine phosphorylase expression in cutaneous squamous cell carcinoma.
Methylthioadenosine phosphorylase gene is silenced by promoter hypermethylation in human lymphoma cell line DHL-9: another mechanism of enzyme deficiency.
Methylthioadenosine phosphorylase inactivation depends on gene deletion in laryngeal squamous cell carcinoma.
Methylthioadenosine phosphorylase regulates ornithine decarboxylase by production of downstream metabolites.
Methylthioadenosine phosphorylase, a gene frequently codeleted with p16(cdkN2a/ARF), acts as a tumor suppressor in a breast cancer cell line.
Molecular cloning of the human methylthioadenosine phosphorylase processed pseudogene and localization to 3q28.
MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells.
MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis.
Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target.
Ocular Expression and Distribution of Products of the POAG-Associated Chromosome 9p21 Gene Region.
Pharmacology and mechanism of action of pemetrexed.
Polyamine pathway activity promotes cysteine essentiality in cancer cells.
Presence of methylthioadenosine phosphorylase (MTAP) in hematopoietic stem/progenitor cells: its therapeutic implication for MTAP (-) malignancies.
PRMT5 silencing selectively affects MTAP-deleted mesothelioma: In vitro evidence of a novel promising approach.
Purification and characterization of recombinant human 5'-methylthioadenosine phosphorylase: definite identification of coding cDNA.
Quantification of intermediates of the methionine and polyamine metabolism by liquid chromatography-tandem mass spectrometry in cultured tumor cells and liver biopsies.
Quantitation of cellular metabolic fluxes of methionine.
Quantitative analysis of 5'-deoxy-5'-methylthioadenosine in melanoma cells by liquid chromatography-stable isotope ratio tandem mass spectrometry.
Selective killing of human malignant cell lines deficient in methylthioadenosine phosphorylase, a purine metabolic enzyme.
Selective killing of tumors deficient in methylthioadenosine phosphorylase: a novel strategy.
Selective PRMT5 Inhibitors Suppress Human CD8+ T Cells by Upregulation of p53 and Impairment of the AKT Pathway Similar to the Tumor Metabolite MTA.
SHARPIN-mediated regulation of protein arginine methyltransferase 5 controls melanoma growth.
Specific Targeting of MTAP-Deleted Tumors with a Combination of 2'-Fluoroadenine and 5'-Methylthioadenosine.
Status of methylthioadenosine phosphorylase and its impact on cellular response to L-alanosine and methylmercaptopurine riboside in human soft tissue sarcoma cells.
Strong expression of methylthioadenosine phosphorylase (MTAP) in human colon carcinoma cells is regulated by TCF1/[beta]-catenin.
Studies on the regulation of ornithine decarboxylase in yeast: effect of deletion in the MEU1 gene.
Suppressive effects of tumor cell-derived 5'-deoxy-5'-methylthioadenosine on human T cells.
Synergistic inhibition of polyamine synthesis and growth by difluoromethylornithine plus methylthioadenosine in methylthioadenosine phosphorylase-deficient murine lymphoma cells.
Targeting 5'-deoxy-5'-(methylthio)adenosine phosphorylase by 5'-haloalkyl analogues of 5'-deoxy-5'-(methylthio)adenosine.
Targeting tumors that lack methylthioadenosine phosphorylase (MTAP) activity: Current strategies.
The essential role of methylthioadenosine phosphorylase in prostate cancer.
The methylthioadenosine phosphorylase gene is frequently co-deleted with the p16INK4a gene in acute type adult T-cell leukemia.
The Transition-State Structure for Human MAT2A from Isotope Effects.
Tissue microarray analysis of methylthioadenosine phosphorylase protein expression in melanocytic skin tumors.
Use of alanosine as a methylthioadenosine phosphorylase-selective therapy for T-cell acute lymphoblastic leukemia in vitro.
Usefulness of methylthioadenosine phosphorylase and BRCA-associated protein 1 immunohistochemistry in the diagnosis of malignant mesothelioma in effusion cytology specimens.
Utility of methylthioadenosine phosphorylase immunohistochemical deficiency as a surrogate for CDKN2A homozygous deletion in the assessment of adult-type infiltrating astrocytoma.
[Expression of methylthioadenosine phosphorylase (MTAP) gene and demethylation of its promoter in human colorectal cancer.]
Nevus
Methylthioadenosine phosphorylase represents a predictive marker for response to adjuvant interferon therapy in patients with malignant melanoma.
Nevus, Pigmented
Characterization of methylthioadenosin phosphorylase (MTAP) expression in malignant melanoma.
Osteosarcoma
Methylthioadenosine phosphorylase deficiency in Japanese osteosarcoma patients.
Methylthioadenosine phosphorylase gene deletions are common in osteosarcoma.
Pancreatic Neoplasms
Loss of methylthioadenosine phosphorylase and elevated ornithine decarboxylase is common in pancreatic cancer.
MTAP deficiency-induced metabolic reprogramming creates a vulnerability to co-targeting de novo purine synthesis and glycolysis in pancreatic cancer.
Pancreatitis
Blockade of the trans-sulfuration pathway in acute pancreatitis due to nitration of cystathionine ?-synthase.
Pleural Effusion
Fluorescence in situ hybridization detection of chromosome 22 monosomy in pleural effusion cytology for the diagnosis of mesothelioma.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Deficiency of methylthioadenosine phosphorylase in human leukemic cells in vivo.
Detection of methylthioadenosine phosphorylase (MTAP) and p16 gene deletion in T cell acute lymphoblastic leukemia by real-time quantitative PCR assay.
EFA (9-beta-D-erythrofuranosyladenine) is an effective salvage agent for methylthioadenosine phosphorylase-selective therapy of T-cell acute lymphoblastic leukemia with L-alanosine.
Frequent deletion in the methylthioadenosine phosphorylase gene in T-cell acute lymphoblastic leukemia: strategies for enzyme-targeted therapy.
Homozygous loss of the interferon genes defines the critical region on 9p that is deleted in lung cancers.
Methylthioadenosine phosphorylase (MTAP)-deficient T-cell ALL xenografts are sensitive to pralatrexate and 6-thioguanine alone and in combination.
Methylthioadenosine phosphorylase as target for chemoselective treatment of T-cell acute lymphoblastic leukemic cells.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Use of alanosine as a methylthioadenosine phosphorylase-selective therapy for T-cell acute lymphoblastic leukemia in vitro.
Prostatic Neoplasms
Next generation sequencing of prostate cancer from a patient identifies a deficiency of methylthioadenosine phosphorylase, an exploitable tumor target.
Pharmacological polyamine catabolism upregulation with methionine salvage pathway inhibition as an effective prostate cancer therapy.
The essential role of methylthioadenosine phosphorylase in prostate cancer.
Protein Deficiency
Characterization and Prognostic Significance of Methylthioadenosine Phosphorylase Deficiency in Nasopharyngeal Carcinoma.
Downregulated MTAP expression in myxofibrosarcoma: A characterization of inactivating mechanisms, tumor suppressive function, and therapeutic relevance.
Retinoblastoma
Lymphoblastic leukemia with lymphomatous features associated with abnormalities of the short arm of chromosome 9.
s-methyl-5'-thioadenosine phosphorylase deficiency
5'-Deoxy-5'-methylthioadenosine phosphorylase and p16INK4 deficiency in multiple tumor cell lines.
5'-deoxy-5'-methylthioadenosine phosphorylase deficiency in leukemia: genetics and biochemical aspects.
5'-Methylthioadenosine phosphorylase deficiency in malignant cells: recessive expression of the defective phenotype in intraspecies (mouse X mouse) hybrids.
Characterization and Prognostic Significance of Methylthioadenosine Phosphorylase Deficiency in Nasopharyngeal Carcinoma.
Downregulated MTAP expression in myxofibrosarcoma: A characterization of inactivating mechanisms, tumor suppressive function, and therapeutic relevance.
Methylthioadenosine nucleoside phosphorylase deficiency in methylthio-dependent cancer cells.
Methylthioadenosine phosphorylase deficiency in acute leukemia: pathologic, cytogenetic, and clinical features.
Methylthioadenosine phosphorylase deficiency in human leukemias and solid tumors.
Methylthioadenosine phosphorylase deficiency in human non-small cell lung cancers.
Methylthioadenosine phosphorylase deficiency in Japanese osteosarcoma patients.
The diagnostic value of immunohistochemically detected methylthioadenosine phosphorylase deficiency in malignant pleural mesotheliomas.
Sarcoma
Status of methylthioadenosine phosphorylase and its impact on cellular response to L-alanosine and methylmercaptopurine riboside in human soft tissue sarcoma cells.
Sarcoma 180
5'-deoxy-5'-methylthioadenosine phosphorylase--V. Acycloadenosine derivatives as inhibitors of the enzyme.
5-Iodoribose 1-phosphate, an analog of ribose 1-phosphate. Enzymatic synthesis and kinetic studies with enzymes of purine, pyrimidine, and sugar phosphate metabolism.
Substrate specificities of 5'-deoxy-5'-methylthioadenosine phosphorylase from Trypanosoma brucei brucei and mammalian cells.
Squamous Cell Carcinoma of Head and Neck
Expression and localisation of methylthioadenosine phosphorylase (MTAP) in oral squamous cell carcinoma and their significance in epithelial-to-mesenchymal transition.
Methylthioadenosine phosphorylase inactivation depends on gene deletion in laryngeal squamous cell carcinoma.
Trypanosomiasis
Leishmania infantum 5'-Methylthioadenosine Phosphorylase presents relevant structural divergence to constitute a potential drug target.
Trypanosomiasis, Bovine
In vivo efficacies of 5'-methylthioadenosine analogs as trypanocides.
Tuberculosis
Identification of Rv0535 as methylthioadenosine phosphorylase from Mycobacterium tuberculosis.